Abstract: SA-PO1107
Desidustat for Correction of Functional Iron Deficiency and Iron Sequestration in Patients with CKD Stage 5 on Maintenance Haemodialysis (CKD-5D)
Session Information
- Kidney Replacement Therapy and Care Delivery Innovations
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 801 Dialysis: Hemodialysis and Frequent Dialysis
Authors
- Jhajhria, Anil Kumar, Rama Medical College Hospital and Research Centre Hapur, Hapur, UP, India
- Choudhary, Shipra, Yashoda Super Speciality Hospital, Kaushambi, UP, India
- Chugh, Nishkarsh, Rama Medical College Hospital and Research Centre Hapur, Hapur, UP, India
- Dassi, Manisha, Max Super Speciality Hospital, Ghaziabad, Uttar Pradesh, India
Background
Functional iron deficiency is common in CKD-5D patients. It is due to chronic inflammation causing hepcidin upregulation, which inhibits gut absorption of iron & also inhibits release of iron from its stored pool. Desidustat is a Hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) , which by stabilizing HIF increases endogenous erythropoietin secretion & suppresses hepcidin. In this study, we used Desidustat and compared it with standard of care in correcting iron sequestration and functional iron deficiency.
Methods
This was a multi-center retrospective cohort study. Data was collected for period of May 2023 to August 2024 . This study included CKD-5D adults, (age >18 years) with anemia & with dialysis vintage of >3 months. Patients were divided into 2 groups – 1st group was Desidustat group (group size- 59) & 2nd group was current standard practice i.e. erythropoietin (EPO) (group size – 154). Both groups received I/V iron therapy in proactive based fashion till ferritin >700 ug/L, TSat >40%. Dosing of EPO was as per KDIGO. Desidustat was started at a dose of 100 mg thrice/week and titrated as per hemoglobin (Hb). Patients were on monthly monitoring of Hb. Ferritin & T sat were done at baseline and 3 monthly.
Results
The baseline characteristics were comparable between the two groups. There was no significant difference in the Hb, ferritin & T sat at baseline. There was no significant difference im the rise of Hb between the two groups. (Desidustat – 3 gram over 6 months vs 2.8 gram in EPO group). There was significant difference in ferritin levels at 6 months in the both groups. Ferritin (380 µg/L in desidustat group with 58 µg/L decreases from baseline vs 558 µg/L in EPO group, with 110 µg/L increase from baseline) while T sat level were comparable (T sat 30 % in desidustat group, 6% rise from baseline vs 33% in EPO group, 7 % rise from baseline).
Conclusion
This study demonstrates that Desidustat achieves desired hemoglobin levels with significantly less iron sequestration in comparison to EPO group in patients of CKD 5-D with anemia. Patient receiving desidustat may be switched to I/V iron given in a reactive fashion as it will be more cost effective as well as avoid long term oxidative stress of iron sequestration while also avoiding the ill effects of supraphysiological exogenous erythropoietin.